SRC and glioblastoma: ATP-competitive SRC inhibitor 70 (Fig. 17), a derivative of 63, has been studied as a potential treatment for glioblastoma, both in vitro and in vivo, demonstrating good growth inhibition effects, while also being well tolerated and having low off-target toxicity.12170 has been evaluated in a series of invasive patient-derived glioblastoma cell lines, two from the invasive region and a further obtained from the core region of the tumour.